Show simple item record

dc.contributor.author Gilbert, P
dc.contributor.author Wang, M
dc.contributor.author Wrin, T
dc.contributor.author Petropoulos, C
dc.contributor.author Gurwith, M
dc.contributor.author Sinangil, F
dc.contributor.author D'Souza, P
dc.contributor.author Rodriguez-Chavez, IR
dc.contributor.author DeCamp, A
dc.contributor.author Giganti, M
dc.contributor.author Berman, PW
dc.contributor.author Self, SG
dc.contributor.author Montefiori, DC
dc.coverage.spatial United States
dc.date.accessioned 2011-06-21T17:27:22Z
dc.date.issued 2010-08-15
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/20608874
dc.identifier.citation J Infect Dis, 2010, 202 (4), pp. 595 - 605
dc.identifier.uri http://hdl.handle.net/10161/4155
dc.description.abstract BACKGROUND: A candidate vaccine consisting of human immunodeficiency virus type 1 (HIV-1) subunit gp120 protein was found previously to be nonprotective in an efficacy trial (Vax004) despite strong antibody responses against the vaccine antigens. Here we assessed the magnitude and breadth of neutralizing antibody responses in Vax004. METHODS: Neutralizing antibodies were measured against highly sensitive (tier 1) and moderately sensitive (tier 2) strains of HIV-1 subtype B in 2 independent assays. Vaccine recipients were stratified by sex, race, and high versus low behavioral risk of HIV-1 acquisition. RESULTS: Most vaccine recipients mounted potent neutralizing antibody responses against HIV-1(MN) and other tier 1 viruses. Occasional weak neutralizing activity was detected against tier 2 viruses. The response against tier 1 and tier 2 viruses was significantly stronger in women than in men. Race and behavioral risk of HIV-1 acquisition had no significant effect on the response. Prior vaccination had little effect on the neutralizing antibody response that arose after infection. CONCLUSIONS: Weak overall neutralizing antibody responses against tier 2 viruses is consistent with a lack of protection in this trial. The magnitude and breadth of neutralization reported here should be useful for identifying improved vaccines.
dc.format.extent 595 - 605
dc.language ENG
dc.language.iso en_US en_US
dc.relation.ispartof J Infect Dis
dc.relation.isversionof 10.1086/654816
dc.subject AIDS Vaccines
dc.subject Antibodies, Neutralizing
dc.subject Female
dc.subject HIV Antibodies
dc.subject HIV Envelope Protein gp120
dc.subject HIV-1
dc.subject Humans
dc.subject Male
dc.subject Neutralization Tests
dc.title Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.
dc.title.alternative en_US
dc.type Journal Article
dc.description.version Version of Record en_US
duke.date.pubdate 2010-8-15 en_US
duke.description.endpage 605 en_US
duke.description.issue 4 en_US
duke.description.startpage 595 en_US
duke.description.volume 202 en_US
dc.relation.journal Journal of Infectious Diseases en_US
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/20608874
pubs.issue 4
pubs.organisational-group /Duke
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery/Surgery, Surgical Sciences Section for AIDS Research & Development
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers/Duke Human Vaccine Institute
pubs.publication-status Published
pubs.volume 202
dc.identifier.eissn 1537-6613

Files in this item

This item appears in the following Collection(s)

Show simple item record